title: A drug safety evaluation of mirabegron in the management of overactive bladder.
abstract: BACKGROUND
  Overactive Bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence and is usually associated with frequency and nocturia. Antimuscarinics are currently the most widely prescribed drugs for OAB although persistence with medication is often limited due to lack of efficacy or intolerable adverse effects. Mirabegron is β3 adrenoreceptor agonist that is the first new drug licensed for the management of overactive bladder (OAB) in over 30 years.
  
  
  METHODS
  This review provides a comprehensive overview of the mirabegron clinical trials programme, including Phase II, III and IV studies with a particular focus on tolerability and safety. A literature search was performed in Pubmed using the key words 'mirabegron', 'overactive bladder', 'β3 adrenoceptor agonist' and 'detrusor overactivity' with no restriction on dates.
  
  
  CONCLUSIONS
  The extensive clinical trial programme has shown mirabegron to be safe and efficacious in the treatment of OAB symptoms and the evidence would suggest that it offers an effective alternative to antimuscarinic therapy.
authors.affiliation: a Department of Urogynaecology , Kings College Hospital , London , UK.
authors.forename: Dudley
authors.initials: D
authors.lastname: Robinson
authors.affiliation: a Department of Urogynaecology , Kings College Hospital , London , UK.
authors.forename: Ganesh
authors.initials: G
authors.lastname: Thiagamoorthy
authors.affiliation: a Department of Urogynaecology , Kings College Hospital , London , UK.
authors.forename: Linda
authors.initials: L
authors.lastname: Cardozo
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D018727:Muscarinic Antagonists; D013844:Thiazoles; C520025:mirabegron
keywords: Mirabegron; overactive bladder; urinary incontinence; β3 adrenoceptor agonist